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 Abstract  
Inhibitors of various elements of the DNA repair pathways have entered clinical development or are 
in late pre-clinical stages of drug development.  It was initially considered that agents targeting DNA 
repair would act to overcome tumour resistance to chemotherapy and radiotherapy. More recent 
data has shown that targeting DNA repair pathways can be effective in selected tumours via a 
synthetically lethal route – with single agent activity having been demonstrated with PARP 
inhibitors.  An increased understanding of the biology and interaction of the DNA repair pathways 
also means that rationale combination of DNA repair inhibitors may also give great benefit in the 
clinic. 
  
Introduction 
Repair of DNA and thus preservation of the genetic code is critical for normal cellular function.  To 
this end human cells have at least 5 recognised pathways which protect the genome by signalling 
specific types of DNA damage and carrying out repair (reviewed in (1-3)).  In cancer cells these 
pathways represent a curious dichotomy – it is well recognised that mutations in the pathways can 
predispose to cancer and are hallmarks of many of the hereditary cancer syndromes (4-6).  However, 
once an immortalised tumour cell has developed, the DNA repair pathways can be used by this cell 
to overcome many of our standard anticancer treatments and hence are a cause of treatment 
resistance.  There is increasing evidence in the literature that tumour tissue has high levels of some 
elements of the DNA repair pathways (7, 8), being able to use these pathways to repair damage 
caused by many of our standard anticancer therapies.  Hence inhibiting DNA repair may “level the 
playing field” and make the tumour more vulnerable to treatment. 
The major DNA repair pathways are direct repair, mismatch repair (MMR), base excision repair 
(BER), nucleotide excision repair (NER), and double strand break recombinational repair which 
includes both non-homologous end joining (NHEJ) and homologous recombinational repair (HHR) (1, 
2, 9).  O
6
-alkylguanine-DNA alkyltransferase (MGMT, OGAT, ATase) is the main component of the 
Direct Repair Pathway, an efficient mechanism of DNA repair where the altered base is corrected 
without removal or disruption of the phosphodiester backbone.  Over expression of ATase in 
mammalian cells confers resistance to DNA alkylating agents (reviewed in (10)), and is a major factor 
in tumour resistance to these drugs.  NER is involved in the repair of UV damage and removal of 
bulky DNA adducts such as those caused by cross-linking agents.  MMR repairs replication errors and 
is frequently mutated in cancer cells allowing tolerance of such lesions (11-13).  BER is involved in 
the repair of single strand breaks, contributing to resistance to ionising radiation and alkylating 
agents.  Recombinational repair has two pathways, the error-free HRR in dividing cells and error-
prone NHEJ active in G1.  These two pathways repair much of the damage caused by radiotherapy 
and chemotherapeutic agents such as cisplatin and mitomycin C (2).   
There are compounds in the clinic or in late preclinical development which inhibit direct repair and 
elements of the base excision and double strand break repair pathways.  The initial development of 
inhibitors of DNA repair pathways was designed to overcome chemo- or radio-resistance (14-19).  
However the increasing knowledge of the complexity and interactions of the DNA damage response 
pathways, as well as the entry of a range of compounds into the clinic has led to a fascinating area of 
drug development – where there are opportunities for improving on existing treatments but also for 
the design of rationale combinations of novel agents to improve treatment response.  Table 1 
demonstrates the range and variety of these DNA damage response modulators which have entered 
the clinic in recent years. 
Chemo-potentiation 
When considering the pipeline of novel agents which over the last 5 year have entered clinical 
development or are at a late preclinical phase it is worth briefly reviewing the earlier trials where 
blocking a DNA repair pathway was the primary aim.  To date a common theme has emerged in the 
majority of trials which appears to be limiting the effectiveness of this strategy- potentiation of 
normal tissue toxicity.  Depletion of MGMT and hence disruption of the direct repair pathway by 
O
6
benzylguanine or lomeguatrib was successfully achieved more than 10 years ago.  These agents 
were combined with carmustine and temozolomide respectively and although pharmacodynamic 
assays confirmed depletion of the target this was achieved at the expense of the chemotherapeutic 
dose (14, 17).  Enhanced normal tissue toxicity in the form of more profound myelosuppression 
meant that a significant reduction in chemotherapy dose was required and phase II studies did not 
demonstrate a benefit in terms of increased tumour response (15, 18).  When the first PARP 
inhibitor in cancer treatment entered the clinic in 2003 it was also evaluated in combination with 
chemotherapy with the initial reports being that a PARP inhibitory dose of drug could be given with 
full dose temozolomide (19).  This was not borne out in the subsequent phase II study where a 25% 
reduction in cytotoxic dose was needed for a tolerable regimen (20).  Although this small study did 
suggest a possible clinical benefit of the combination this has yet to be confirmed in a randomised 
study. 
Enhancement of normal tissue toxicity is emerging as a common theme with some of the other PARP 
inhibitors when combined with chemotherapy.  Studies with ABT888 (veliparib) and AZD2281 
(olaparib) with a range of cytotoxic agents have reported the need to reduce chemotherapy dose 
due to enhanced myelosuppression (21-23).  The outlying data in this area is that from the 
combination of BSI-201 with carboplatin and gemcitabine in triple negative breast cancer where very 
encouraging evidence of increased activity was observed with no increase in toxicity (24, 25).  It has 
been speculated that this may be due to the intermittent schedule of dosing of the PARP inhibitor 
allowing bone marrow recovery.  This would argue for the increased activity being due to chemo-
potentiation rather than single agent PARP activity acting through synthetic lethality on the 
proposed HRR deficient triple negative phenotype as other studies demonstrating single agent 
activity have required continuous and profound PARP inhibition (26-28).  Other agents targeting 
DNA damage response in late preclinical development are entering the clinic (inhibitors of DNA PK, 
ATM, ATR, and RAD51 (29-33)).  These agents have also demonstrated the ability to potentiate the 
activity of cytotoxic drugs in preclinical models, it remains to be seen whether this can be done 
without the increased toxicity and subsequent dose reductions which have been required in many of 
the previous studies.  It may be that it is the area of radio-potentiation that we are able to use these 
powerful inhibitors to fuller potential.  Radiation causes DNA single and double strand breaks, many 
of the DNA repair inhibitors have been shown to be radio-potentiating (29, 30, 34).  The increasing 
use of highly technical radiotherapy techniques (IMRT, IGRT and tomotherapy) may allow 
radiation/inhibitor combination studies where tumour response is improved without consequent 
increase in normal tissue toxicity. 
One of the very exciting developments in the field of DNA damage response research in the last few 
years has been the preclinical (35, 36) and subsequent clinical demonstration (26-28) of the ability to 
cause synthetic lethality in selected cell types using a DNA repair inhibitor without also using a DNA 
damaging agent.  Although this has first been demonstrated with the use of PARP inhibitors in 
patients with familial breast and ovarian cancer carrying the BRCA genes it has opened up the 
possibility that this much less toxic strategy may be a benefit in patients with sporadic tumours if a 
predictive molecular phenotype can be identified.  Many research groups are now working to 
develop functional assays for double strand break repair competence, or molecular signatures which 
will allow enrichment of patient populations within trials.  An additional consequence of this 
pioneering research has been that DNA repair inhibitors have been recognised as potentially active 
anticancer agents in their own right.  With the expanding knowledge of the DNA damage response 
pathways and the plethora of drugs entering clinical development targeting different elements of 
these pathways it will be possible to design trials where novel combinations of repair inhibitors 
including the check point inhibitors (37-39) may be active, or where patients are selected based on 
the oncogenic mutation status of their tumour – for example mutations in ATR, ATM or the Fanconi 
proteins may also predict for sensitivity to PARP inhibitors (40, 41).  Figure 1a summarises in 
simplified form the BER and DSB pathways emphasising the close interactions and cross talk 
between the BER and DSB repair pathways and cell cycle check point signalling.  Figure 1b illustrates 
the currents DNA damage response modulating drugs targeting these pathways and related 
checkpoint signalling illustrating the fascinating potential for rationale combination of these novel 
agents. 
Conclusion 
As the DNA repair inhibitors continue to move forwards in clinical development we need to be able 
to learn from and build on the lessons of history so that the true potential of these drugs is realised.  
It is likely that they will be ultimately be used in combination regimens, the response rates in the 
BRCA population are not at the levels seem in CML and GIST with imatinib. There is, therefore, much 
work to be done exploring scheduling to avoid increased toxicities.  When a DNA damage 
modulating agent is to be used to prevent repair and so potentiate the activity of the cytotoxic agent 
they need to be given concurrently, it may be that pulsed schedules of the modulator would, in this 
situation, cause the desired tumour cell kill but allow normal tissue toxicity to recover.  If the 
modulator is predicted to have single agent activity in a particular disease setting then scheduling 
apart from the cytotoxic with longer duration of coverage might be the optimal route.  The interplay 
between the increasing knowledge of the biology of these pathways and the increasing ability to 
explore the molecular profile of our patients’ tumours using array and circulating tumour cell 
technologies means that this is an exciting, fast moving and potentially very beneficial area of cancer 
treatment research. 
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Figure legends 
Figure 1 Simplified schematic of signalling and repair of single and double DNA strand breaks to 
illustrate the interactions between pathways and potential rational inhibitor combinations.  
Figure 1a Damaged  DNA bases are excised involving APE-1, and single strand break activates PARP 
which recruits other components of BER.  In a dividing cell unrepaired SSB will become DSB.  The 
presence of DS breaks is signalled via the ATM/ATR pathways.  In non-dividing cells G1 arrest is 
signalled via Chk2 and NEHJ pathways repairs the break.  In dividing cells G2 arrest allows error free 
repair using HR. 
 
Figure 1b  Simplified schematic of signalling and repair of single and double DNA strand breaks 
showing the points of action of current inhibitors in the clinic or in late preclinical development.  
Additionally it is highlighted that Chk1 inhibitors have entered the clinic, presenting an opportunity 
to combine these agents with DNA damage response modulators.
Table 1 
DNA damage response modulating drugs in clinical development – grouped by repair pathway targeted.  Data taken from www.clinicaltrials.gov, 
compounds thought to be in late preclinical development also included for completeness. 
 
Agent Company Administration Single/combination 
therapy 
Disease indications Clinical status 
Direct repair (MGMT) 
O
6
benzyguanine   Combination BCNU GBM Phase II complete 
Lomeguatrib KuDos Oral Combination  with TMZ Melanoma Phase II complete 
Single strand break repair (PARP inhibitors, PARPi) 
PF0367338 
(AG014699) 
Pfizer IV Combination ++ single 
agent 
Solid tumours, 
melanoma 
Phase I and II 
complete and others 
on going 
Olaparib (AZD2281) AztraZeneca (KuDos) Oral Combination ++ single 
agent 
BRCA defective, solid 
tumours various 
Phase I and II studies 
completed and on 
going 
Veliparib (ABT888) Abbott Oral Combination ++ Various solid tumours Phase I and II studies 
completed and on 
going 
Iniparib (SAR240550, 
BSI 201) 
Sanofi Aventis (Bipar) IV Combination Triple negative breast Phase III complete 
MK4827 Merck Oral Single agent Solid, BRCA ovarian Phase I ongoing 
CEP-9722 Cephalon  Oral Combination with TMZ Solid tumours Phase I ongoing 
E7016 (GPI 21016) 
 
Eisai (MGI Pharma)  Oral Combination with TMZ Solid tumors  Phase I ongoing 
LT673 Biomarin  Oral  Solid tumours Phase I planned 
Single strand break repair (APE1 inhibitors APE1i) 
TRC102 Tracon Oral Combination with 
pemetrexed 
Solid tumours Phase I complete 
Methoxyamine  IV Combination with TMZ Solid tumours Phase I suspended 
Double strand break repair (RAD51 inhibitor, RAD51i) 
MP470 Supergen Oral Single agent Lymphoma/solid 
tumours 
Phase I ? opened 
Double strand break repair (ATM inhibitor, ATMi) 
KU55933 AstraZeneca (KuDos) ? ? ? preclinical 
CP466722 Pfizer ? ? ? preclinical 
Double strand break repair (DNA PK inhibitor, DNA PKi) 
NU7441 AstraZeneca (KuDos) ? ? ? preclinical 
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